Skip to main navigation

Our Science
Pipeline & Programs
About Us
Life at Arvinas
Patients
Investors + Media

>> Sub navigation

Careers
Contact

Investors + Media: Press Releases

Press Releases

Year

August 7, 2019

Arvinas To Present at the Wedbush PacGrow Healthcare Conference

August 5, 2019

Arvinas Reports Second Quarter 2019 Financial Results and Provides Corporate Update

July 29, 2019

Arvinas Appoints Ronald Peck, M.D. as Chief Medical Officer

July 25, 2019

Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk

July 18, 2019

Arvinas to Present Preclinical Tau-Directed PROTAC® Protein Degrader Data at Alzheimer's Association International Conference

June 25, 2019

Arvinas Receives Authorization to Proceed for ARV-471, a PROTAC® Protein Degrader to Treat Patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer

June 20, 2019

Arvinas to Present at the BMO Prescriptions for Success Healthcare Conference

June 6, 2019

Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

June 4, 2019

Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications

May 29, 2019

Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Tools

Email Alerts
RSS Feeds
Print Page
Email Page

Leading the way in targeted protein degradation therapeutics.

Join our team of experts

Follow Us https://www.linkedin.com/company/arvinas/ https://twitter.com/ArvinasInc

©2020. All Rights Reserved.

Contact Privacy Policy Terms & Conditions